Your session is about to expire
← Back to Search
Intravenous Challenge Drug: Hydromorphone for Opioid Use Disorder
Study Summary
This trial is testing the abuse potential of the drug oxymorphone in comparison to other opioids. It is designed to study the reinforcing effects of the drug among physically dependent opioid abusers.
- Opioid Use Disorder
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Are there still vacancies to enter this trial?
"Per the information on clinicaltrials.gov, this particular trial is no longer taking applicants; initial posting was done on March 15th 2018 and the most recent update occurred September 1st 2022. However, there are 291 other medical trials actively recruiting patients at present."
Is there an age restriction for participation in this research trial?
"This clinical trial necessitates that all participants be between 21 and 55 years of age. There are 22 trials available for those below the legal age, while 240 studies cater to seniors beyond 65."
Are there any particular participants who are ideal for this trial?
"This clinical trial is seeking 20 opioid addicts, aged between 21 and 55 years old. To be eligible for the study, patients must meet specific criteria including: capacity to comprehend and provide a digitally signed consent form; self-reported illicit use of opioids on at least 3 weeks in the month preceding screening; physical dependence on opioids; recent intravenous opioid consumption; meeting DSM 5 criteria for moderate-severe opioid abuse disorder; BMI ranging from 18 to 35 kg/m2 with weight over 50kg (110 lbs); general health as determined by an investigator; women able to prove they are not pregnant or breastfeeding during screening stage; willingness and capability of"
What potential risks are associated with the administration of intravenous Morphine?
"With Phase 2 evidence providing a baseline of safety, our team at Power rated Intravenous Challege Drug: Morphine as a 2 on the 3-point scale. Clinical data does not yet provide indications that this medication is efficacious."
Share this study with friends
Copy Link
Messenger